Bryan P. Schneider

Bryan P. Schneider

Auto-generated profile, based on publicly available information

Bryan P. Schneider

Department of Hematology and Oncology, Indiana University School of Medicine, Indianapolis, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2008 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
BSBryan P. Schneider
Bryan P. Schneider
MWMolin Wang
Molin Wang
MRMilan Radovich
Milan Radovich
GSGeorge W. Sledge
George W. Sledge
Sunil S BadveSunil S Badve
Sunil S Badve
KMKathy D. Miller
Kathy D. Miller
Purpose: No biomarkers have been identified to predict outcome with the use of an antiangiogenesis agent for cancer. Vascular endothelial growth factor (VEGF) genetic variability has been associated with altered risk of breast cancer and variable promoter activity. Therefore, we evaluated the association of VEGF genotype with efficacy and toxicity in E2100, a phase III study comparing paclitaxel versus paclitaxel plus bevacizumab as initial chemotherapy for metastatic breast cancer. Patients and Methods: DNA was extracted from tumor blocks of patients from E2100. Three hundred sixty-three samples were available to evaluate associations between genotype and outcome. Genotyping was performed for selected polymorphisms in VEGF and VEGF receptor 2. Testing for associations between each polymorphism and efficacy and toxicity was performed. Results: The VEGF-2578 AA genotype was associated with a superior median overall survival (OS) in the combination arm when compared with the alternate genotypes combined (hazard ratio = 0.58; 95% CI, 0.36 to 0.93; P = .023). The VEGF-1154 A allele also demonstrated a superior median OS with an additive effect of each active allele in the combination arm but not the control arm (hazard ratio = 0.62; 95% CI, 0.46 to 0.83; P = .001). Two additional genotypes, VEGF-634 CC and VEGF-1498 TT, were associated with significantly less grade 3 or 4 hypertension in the combination arm when compared with the alternate genotypes combined (P = .005 and P = .022, respectively). Conclusion: Our data support an association between VEGF genotype and median OS as well as grade 3 or 4 hypertension when using bevacizumab in metastatic breast cancer.

15 December 2008 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
BSBryan P. Schneider
Bryan P. Schneider
EWEric P. Winer
Eric P. Winer
WFWilliam Foulkes
William Foulkes
JGJudy Garber
Judy Garber
CPCharles M Perou
Charles M Perou
LCLisa A. Carey
Lisa A. Carey
Triple-negative breast cancer has recently been recognized as an important subgroup of breast cancer with a distinct outcome and therapeutic approach when compared with other subgroups of breast cancer. Triple-negative breast cancer comprises primarily, but not exclusively, a molecularly distinct subtype of breast cancer, the basal-like subtype. We do not yet have an assay to identify basal-like breast cancer in clinical samples, so triple-negative breast cancer has become a commonly used proxy for this subtype. The molecular biology and pathophysiology of triple-negative breast cancer are not completely understood, but understanding is improving rapidly with the advent of sophisticated molecular biology platforms. Moreover, the established risk factors of breast cancer as a whole may not apply to this unique subgroup of patients. Finally, because triple-negative breast cancer is defined by the absence of a target, there are currently limitations to using a tailored therapeutic approach, leaving conventional cytotoxic therapies as the mainstay. Active preclinical and clinical research programs focus on defining the clinical behavior, delineating the risk factors, and more completely understanding the molecular biology of triple-negative breast cancer to improve prevention, optimize conventional agents, and unveil novel therapeutic targets. This CCR focus article will review the current state of the art on triple-negative breast cancer.

1 September 2020 in JAMA Oncology
Verified
Journal Article
Open access
PDF file
MRMilan Radovich
Milan Radovich
GJGuanglong Jiang
Guanglong Jiang
BHBradley A. Hancock
Bradley A. Hancock
CCChristopher Chitambar
Christopher Chitambar
RNRita Nanda
Rita Nanda
BSBryan P. Schneider
Bryan P. Schneider
A large proportion of patients with triple-negative breast cancer (TNBC) are treated with neoadjuvant chemotherapy. Approximately one-third of patients will achieve a pathologic complete response with neoadjuvant chemotherapy and have favorable outcomes. In contrast, two-thirds of patients will have residual disease and are at high risk of relapse.1 Methods that can detect the presence of minimal residual disease (MRD) in the circulation after surgery may be used to determine in which patients disease will recur.

10 March 2005 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PDF file
BSBryan P. Schneider
Bryan P. Schneider
KMKathy D. Miller
Kathy D. Miller

12 November 2015 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
BSBryan P. Schneider
Bryan P. Schneider
LLLang Li
Lang Li
MRMilan Radovich
Milan Radovich
FSFei Shen
Fei Shen
KMKathy D. Miller
Kathy D. Miller
GSGeorge W. Sledge
George W. Sledge
Purpose: Taxane-induced peripheral neuropathy (TIPN) is an important survivorship issue for many cancer patients. Currently, there are no clinically implemented biomarkers to predict which patients might be at increased risk for TIPN. We present a comprehensive approach to identification of genetic variants to predict TIPN. Experimental Design: We performed a genome-wide association study (GWAS) in 3,431 patients from the phase III adjuvant breast cancer trial, ECOG-5103 to compare genotypes with TIPN. We performed candidate validation of top SNPs for TIPN in another phase III adjuvant breast cancer trial, ECOG-1199. Results: When evaluating for grade 3–4 TIPN, 120 SNPs had a P value of <10−4 from patients of European descent (EA) in ECOG-5103. Thirty candidate SNPs were subsequently tested in ECOG-1199 and SNP rs3125923 was found to be significantly associated with grade 3–4 TIPN (P = 1.7 × 10−3; OR, 1.8). Race was also a major predictor of TIPN, with patients of African descent (AA) experiencing increased risk of grade 2–4 TIPN (HR, 2.1; P = 5.6 × 10−16) and grade 3–4 TIPN (HR, 2.6; P = 1.1 × 10−11) compared with others. An SNP in FCAMR, rs1856746, had a trend toward an association with grade 2–4 TIPN in AA patients from the GWAS in ECOG-5103 (OR, 5.5; P = 1.6 × 10−7). Conclusions: rs3125923 represents a validated SNP to predict grade 3-4 TIPN. Genetically determined AA race represents the most significant predictor of TIPN. Clin Cancer Res; 21(22); 5082–91. ©2015 AACR.

20 July 2021 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
STSara M. Tolaney
Sara M. Tolaney
NTNabihah Tayob
Nabihah Tayob
CDChau Dang
Chau Dang
DYDenise A. Yardley
Denise A. Yardley
SISteven J. Isakoff
Steven J. Isakoff
IKIan Krop
Ian Krop
PURPOSE: The ATEMPT trial was designed to determine if treatment with trastuzumab emtansine (T-DM1) caused less toxicity than paclitaxel plus trastuzumab (TH) and yielded clinically acceptable invasive disease-free survival (iDFS) among patients with stage I human epidermal growth factor receptor 2–positive (HER2+) breast cancer (BC). METHODS: Patients with stage I centrally confirmed HER2+ BC were randomly assigned 3:1 to T-DM1 or TH and received T-DM1 3.6 mg/kg IV every 3 weeks for 17 cycles or T 80 mg/m2 IV with H once every week × 12 weeks (4 mg/kg load →2 mg/kg), followed by H × 39 weeks (6 mg/kg once every 3 weeks). The co-primary objectives were to compare the incidence of clinically relevant toxicities (CRTs) in patients treated with T-DM1 versus TH and to evaluate iDFS in patients receiving T-DM1. RESULTS: The analysis population includes all 497 patients who initiated protocol therapy (383 T-DM1 and 114 TH). CRTs were experienced by 46% of patients on T-DM1 and 47% of patients on TH ( P = .83). The 3-year iDFS for T-DM1 was 97.8% (95% CI, 96.3 to 99.3), which rejected the null hypothesis ( P < .0001). Serially collected patient-reported outcomes indicated that patients treated with T-DM1 had less neuropathy and alopecia and better work productivity compared with patients on TH. CONCLUSION: Among patients with stage I HER2+ BC, one year of adjuvant T-DM1 was associated with excellent 3-year iDFS, but was not associated with fewer CRT compared with TH.